Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Myeloid 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 2

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Tyrosine Kinase Inhibitors × Gynecologic × Clear all
NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Sun Yat-sen University

Phase 1/2 Completed
29 enrolled
Gynecologic

Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
123 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡